CD4 and neoplasm: Notably, primarily resected tumors are not the ideal control for comparison with more advanced tumors from patients who receive NEO, potentially explaining why there was no observable difference in the percentage of tumor-infiltrating CD8+ and CD4+ T cells between the PR and NEO cohort.